Erratum: Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study (The Lancet (2016) 388(10050) (1161–1169)(S0140673616309680)(10.1016/S0140-6736(16)30968-0));Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study

The Lancet

Volumn 388, Issue 10050, 2016, Pages 1161-1169

  Healey, Jeff S ^a   Oldgren, Jonas ^b   Ezekowitz, Michael ^c   Zhu, Jun ^d   Pais, Prem ^e   Wang, Jia ^a   Commerford, Patrick ^f   Jansky, Petr ^g   Avezum, Alvaro ^h   Sigamani, Alben ^e   Demasceno, Albertino ⁱ   Reilly, Paul ^j   Grinvalds, Alex ^a   Nakamya, Juliet ^a   Aje, Akinyemi ^k   Almahmeed, Wael ^l   Moriarty, Andrew ^m   Wallentin, Lars ^b   Yusuf, Salim ^a   Connolly, Stuart J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b Uppsala Clinic Hospital   (Sweden)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d FUWAI HOSPITAL   (China)

^e ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^h Instituto de Cardiologia Dante Pazzanese   (Brazil)

ⁱ EDUARDO MONDLANE UNIVERSITY   (Mozambique)

^j BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^k UNIVERSITY OF IBADAN   (Nigeria)

^l SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^m CRAIGAVON AREA HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; AFRICA SOUTH OF THE SAHARA; ARTICLE; ATRIAL FIBRILLATION; AUSTRALIA; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; EASTERN EUROPE; EMERGENCY WARD; FEMALE; FOLLOW UP; HEART ATRIUM FLUTTER; HEART FAILURE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; MORBIDITY; MORTALITY; NORTH AMERICA; PRIORITY JOURNAL; RHEUMATIC HEART DISEASE; SOUTH AMERICA; SOUTHEAST ASIA; WESTERN EUROPE; ADULT; AGED; COMORBIDITY; COMPLICATION; GLOBAL HEALTH; INCIDENCE; MIDDLE AGED; STROKE;

ADULT; AGED; ATRIAL FIBRILLATION; COHORT STUDIES; COMORBIDITY; DEATH; FEMALE; GLOBAL HEALTH; HUMANS; INCIDENCE; MALE; MIDDLE AGED; STROKE;

EID: 84992436641     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31789-5     Document Type: Erratum

References (44)

1. 1 Wolf, PA, Abbot, RD, Kannel, WB, Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med 147 (1987), 1561–1564.
2. 2 Krahn, AD, The natural history of atrial fibrillation: Incidence, risk factors and prognosis in the Manitoba Follow-up Study. Am J Med 98 (1995), 476–484.
3. 3 Benjamin, EJ, Wolf, PA, D'Agostino Sr, RB, Silbershatz, H, Kannel, WB, Levy, D, Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98 (1998), 946–952.
4. 4 Wolf, PA, Abbot, RD, Kannel, WB, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991), 983–988.
5. 5 Dentali, F, Riva, N, Crowther, M, Turpie, AG, Lip, GY, Ageno, W, Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 126 (2012), 2381–2391.
6. 6 Hart, RG, Pearce, LA, Aquilar, MI, Meta-analysis: anti-thrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
7. 7 Nieuwlaat, R, Capucci, A, Camm, AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26 (2005), 2422–2434.
8. 8 Connolly, SJ, Ezekowitz, MD, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
9. 9 Granger, CB, Alexander, JH, McMurrary, JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
10. 10 Fuster, V, Ryden, LE, Cannom, DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 48 (2006), 854–906.
11. 11 Skanes, AC, Healey, JS, Cairns, JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 28 (2012), 125–136.
12. 12 Wann, LS, Curtis, AB, January, CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 8 (2011), 157–176.
13. 13 Pilote, L, Eisenberg, MJ, Essebag, V, et al. Temporal trends in medication use and outcomes in atrial fibrillation. Can J Cardiol 29 (2013), 1241–1248.
14. 14 Le Heuzey, JY, Breithardt, G, Camm, AJ, et al. The RECORDAF study: Design, baseline data and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol 105 (2010), 687–693.
15. 15 Zubaid, M, Rashed, WA, Alsheik-Ali, AA, et al. Gulf survey of atrial fibrillation events (Gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East. Circ Cardiovasc Qual Outcomes 4 (2011), 477–482.
16. 16 Ntep-Gweth, M, Zimmermann, M, Meiltz, A, Kingue, S, Ndobo, P, Bloch, A, Atrial fibrillation in Africa: clinical characteristics, prognosis and adherence to guidelines in Cameroon. Europace 12 (2010), 482–487.
17. 17 Oldgren, J, Healey, JS, Ezekowitz, MD, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15 400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 129 (2014), 1568–1576.
18. 18 World Bank. World Bank list of economies 2011. http://wdronline.worldbank.org/worldbank/a/incomelevel (accessed Dec 14, 2015).
19. 19 Jones, WJ, Williams, LS, Meschia, JF, Validating the questionnaire for verifying stroke-free status (QVSFS) by neurologic history and examination. Stroke 32 (2001), 2232–2236.
20. 20 The World Bank. GDP per capita (constant 2005 US$). World Bank National Accounts data and OECD National Accounts Data Files. http://data.worldbank.org/indicator/NY.GDP.PCAP.KD, 2014 (accessed Dec 14, 2015).
21. 21 Hannan, EL, Wu, C, DeLong, ER, Raudenbush, SW, Predicting risk-adjusted mortality for CABG surgery: logistic versus hierarchical logistic models. Med Care 43 (2005), 726–735.
22. 22 Merlo, J, Chaix, B, Ohlsson, H, et al. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Epidemiol Community Health 60 (2006), 290–297.
23. 23 Atzema, CL, Lam, K, Young, C, Kester-Greene, N, Patients with atrial fibrillation and an alternative primary diagnosis in the emergency department: a description of their characteristics and outcomes. Acad Emerg Med 20 (2013), 193–199.
24. 24 McDonald, AJ, Pelletier, AJ, Ellinor, PT, Camargo, CA Jr, Increasing US emergency department visit rates and subsequent hospital admissions for atrial fibrillation from 1993–2004. Ann Emerg Med 51 (2014), 58–65.
25. 25 Giugliano, RP, Ruff, CT, Braunwald, E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
26. 26 Patel, MR, Mahaffey, KW, Garg, J, et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
27. 27 Boriani, G, Laroche, C, Diemberger, I, et al. Real-world management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EROP-AF) General Pilot Registry. Europace 18 (2016), 648–657.
28. 28 Zubaid, M, Rashed, WA, Alsheikh-Ali, AA, et al. Management and 1-year outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events. Angiology 66 (2015), 464–471.
29. 29 Ntep-Gweth, M, Zimmermann, M, Meiltz, A, et al. Atrial fibrillation in Africa: clinical characteristics, prognosis and adherence to guidelines in Cameroon. Europace 12 (2010), 482–484.
30. 30 Larsen, TB, Lip, GY, Skjoth, F, Due, KM, Overvad, K, Hvilsted Rasmussen, L, Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer and Health cohort study. Circ Cardiovasc Qual Outcomes 5 (2012), 335–342.
31. 31 Friberg, L, Benson, L, Lip, GY, Balancing stroke and bleeding risk in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 36 (2015), 297–306.
32. 32 Neal, B, MacMahon, S, Chapman, N, Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 356 (2000), 1955–1964.
33. 33 Hart, RG, Pearce, LA, Aguilar, MI, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
34. 34 Ruff, CT, Giugliano, RP, Braunwald, E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
35. 35 Chow, CK, Teo, KK, Rangarajan, S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle- and low-income countries. JAMA 310 (2013), 959–968.
36. 36 Healey, JS, Wharton, S, Al-Kaabi, S, et al. Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialists. Can J Cardiol 22 (2006), 485–488.
37. 37 Kaczorowski, J, Chambers, LW, Dolovich, L, et al. Improving cardiovascular health at population level: 39 community cluster randomised trial of cardiovascular health awareness program (CHAP). BMJ, 342, 2011, d442.
38. 38 Bungard, TJ, Ghali, WA, Teo, KK, McAlister, FA, Tsuyuki, RT, Why do patients with atrial fibrillation not receive warfarin?. Arch Intern Med 160 (2000), 41–46.
39. 39 Ezekowitz, JA, Van Walraven, C, McAlister, FA, Armstrong, PW, Kaul, P, Impact of specialist follow-up in outpatients with congestive heart failure. CMAJ 172 (2005), 189–194.
40. 40 Marijon, E, Mirabel, M, Celermajer, DS, Jouven, X, Rheumatic heart disease. Lancet 379 (2012), 953–964.
41. 41 Wolf, PA, Dawber, TR, Thomas, HE Jr, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology 28 (1978), 973–977.
42. 42 Webb, R, Wilson, NJ, Lennon, D, Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 357 (2007), 470–476.
43. 43 Diker, E, Aydogdu, S, Ozdemir, M, et al. Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. Am J Cardiol 77 (1996), 96–98.
44. 44 Kakkar, AK, Mueller, I, Bassand, JP, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One, 8, 2013, e63479.